Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 23, Issue 2, Pages 520-529
Publisher
Wiley
Online
2020-11-03
DOI
10.1111/dom.14245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018
- (2020) Chintan V. Dave et al. DIABETES CARE
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
- (2020) Jakob S. Knudsen et al. PLoS One
- The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
- (2020) Peter Bramlage et al. BMJ Open Diabetes Research & Care
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
- (2019) Suzanne V. Arnold et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- The Danish health care system and epidemiological research: from health care contacts to database records
- (2019) Morten Schmidt et al. Clinical Epidemiology
- Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice
- (2019) Antonio Nicolucci et al. ADVANCES IN THERAPY
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
- (2019) Rozalina G. McCoy et al. Diabetes Technology & Therapeutics
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease
- (2018) Kevin M. Pantalone et al. Cardiovascular Diabetology
- The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17
- (2018) Adrian H. Heald et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Diabetes Drugs and the Cardiovascular Specialist
- (2017) Naveed Sattar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study
- (2017) Reimar W Thomsen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- (2017) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes MellitusHighlights
- (2016) Kazuyuki Yahagi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study
- (2016) Kasper Adelborg et al. BMJ Open
- Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study
- (2016) Jens Sundbøll et al. BMJ Open
- Comprehensive Cardiovascular Risk Factor Control Improves Survival
- (2015) Vera Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes, Glycemic Control, and Risk of Tuberculosis: A population-based case-control study
- (2011) A. Leegaard et al. DIABETES CARE
- Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk
- (2008) Tina Ken Schramm et al. CIRCULATION
- Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study
- (2008) H. T. Horsdal et al. DIABETOLOGIA
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
- (2008) M. R. MacDonald et al. EUROPEAN HEART JOURNAL
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started